Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided step-up Teclistamab + Daratumumab ± Lenalidomide in Newly Diagnosed Multiple Myeloma (ASCT-ineligible)
KCT0009989Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of teclistamab, daratumumab, lenalidomide in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Dec 2025; status: recruiting.
02
Drugs
teclistamabdaratumumablenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0009989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009989.